HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Diminished ovarian reserve — Clinical Guidelines

Overview

Diminished ovarian reserve (DOR) refers to a reduced number of remaining oocytes in the ovaries, often indicated by lower levels of anti-Müllerian hormone (AMH) and decreased antral follicle count, leading to potential infertility and earlier menopause. 3

Diagnosis

Key Diagnostic Criteria: Low Anti-Mullerian Hormone (AMH) levels, elevated FSH levels, reduced antral follicle count on ultrasound.

Recommended Tests: Serum AMH measurement, FSH levels, estradiol levels, antral follicle count via transvaginal ultrasound.

Grading: AMH levels <1 ng/mL often indicate diminished reserve, though thresholds can vary 3.

Management

First-Line Treatments: Fertility preservation options including oocyte cryopreservation.

Adjunctive Treatments: Vitamin D supplementation in cases of deficiency, potentially improving AMH levels (50,000 units weekly for up to 3 months) 3.

Monitoring: Regular AMH and FSH assessments to track ovarian reserve changes over time.

Special Populations

Pregnancy: No specific data provided in abstracts regarding DOR management during pregnancy.

Pediatrics: Not addressed in provided abstracts.

Elderly: No specific considerations noted for elderly patients in the abstracts.

Comorbidities: No specific guidance provided for managing DOR in patients with comorbidities.

Key Recommendations

Assess AMH and FSH levels for diagnosis of DOR (Evidence: Moderate 3).

Consider vitamin D supplementation for women with DOR and vitamin D deficiency to potentially improve AMH levels (Evidence: Moderate 3).

Educate patients on fertility preservation options, particularly oocyte cryopreservation, especially given resident physicians' varying knowledge and attitudes toward discussing these topics (Evidence: Expert opinion 2 4).

References

1 Gurbuz T, Gokmen O, Devranoglu B, Yurci A, Madenli AA. Artificial intelligence in reproductive endocrinology: an in-depth longitudinal analysis of ChatGPTv4's month-by-month interpretation and adherence to clinical guidelines for diminished ovarian reserve. Endocrine 2024. link 2 Tsai S, Truong T, Eaton JL. Fertility awareness and attitudes among resident physicians across different specialties. Journal of assisted reproduction and genetics 2022. link 3 Aramesh S, Alifarja T, Jannesar R, Ghaffari P, Vanda R, Bazarganipour F. Does vitamin D supplementation improve ovarian reserve in women with diminished ovarian reserve and vitamin D deficiency: a before-and-after intervention study. BMC endocrine disorders 2021. link 4 Yu L, Peterson B, Inhorn MC, Boehm JK, Patrizio P. Knowledge, attitudes, and intentions toward fertility awareness and oocyte cryopreservation among obstetrics and gynecology resident physicians. Human reproduction (Oxford, England) 2016. link

Diminished ovarian reserve